Novel Gut-Based Pharmacology of Metformin in Patients with Type 2 Diabetes Mellitus

• Antonella Napolitano ,

  * E-mail: antonella.2.napolitano@gsk.com

  Affiliation Immuno-Inflammation Unit, GSK R&D, Stevenage, Herts, United Kingdom

  ⨯
• Sam Miller,

  Affiliation Quantitative Sciences, GSK R&D, Stevenage, Herts, United Kingdom

  ⨯
• Andrew W. Nicholls,

  Affiliation Safety Assessment, GSK R&D, Ware, Herts, United Kingdom

  ⨯
• David Baker,

  Affiliation Safety Assessment, GSK R&D, Ware, Herts, United Kingdom

  ⨯
• Stephanie Van Horn,

  Affiliation Target and Pathways Validation, GSK R&D, Upper Providence, Pennsylvania, United States of America

  ⨯
• Elizabeth Thomas,

  Affiliation Target and Pathways Validation, GSK R&D, Upper Providence, Pennsylvania, United States of America

  ⨯
• Deepak Rajpal,

  Affiliation Computational Biology, GSK R&D, Upper Providence, Pennsylvania, United States of America

  ⨯
• Aaron Spivak,

  Affiliation Computational Biology, GSK R&D, Upper Providence, Pennsylvania, United States of America

  ⨯
• James R. Brown,

  Affiliation Computational Biology, GSK R&D, Upper Providence, Pennsylvania, United States of America

  ⨯
• Derek J. Nunez

  Affiliation Enteroendocrine Discovery Unit, GlaxoSmithKline R&D, GSK R&D, Research Triangle Park, North Carolina, United States of America

  ⨯